Logo

OncoMed Licenses MorphoSys HuCal Library to Help Develop Cancer Therapies

Jun 08, 2006

NEW YORK, June 7 (GenomeWeb News) - OncoMed Pharmaceuticals has licensed an antibody library from MorphoSys to research and develop therapeutic antibodies for the treatment of several cancers, the companies said today.

 

According to the terms of the agreement, OncoMed will gain access to MorphoSys' HuCal Gold library for two years in exchange for an up-front payment and annual user fees, the companies said.

 

The firms did not disclose additional financial details.

 

OncoMed will use the library to develop therapies against cancer stem cells in breast, lung, colon, prostate, and other cancers, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.